Singapore markets closed
  • Straits Times Index

    3,204.82
    +2.01 (+0.06%)
     
  • Nikkei

    32,402.41
    -168.62 (-0.52%)
     
  • Hang Seng

    18,057.45
    +402.04 (+2.28%)
     
  • FTSE 100

    7,692.07
    +13.45 (+0.18%)
     
  • Bitcoin USD

    26,671.05
    +77.34 (+0.29%)
     
  • CMC Crypto 200

    568.59
    +0.54 (+0.10%)
     
  • S&P 500

    4,351.87
    +21.87 (+0.51%)
     
  • Dow

    34,128.78
    +58.36 (+0.17%)
     
  • Nasdaq

    13,331.95
    +107.96 (+0.82%)
     
  • Gold

    1,947.70
    +8.10 (+0.42%)
     
  • Crude Oil

    90.02
    +0.39 (+0.44%)
     
  • 10-Yr Bond

    4.4280
    -0.0520 (-1.16%)
     
  • FTSE Bursa Malaysia

    1,450.23
    +2.02 (+0.14%)
     
  • Jakarta Composite Index

    7,016.84
    +25.38 (+0.36%)
     
  • PSE Index

    6,142.79
    +48.08 (+0.79%)
     

Why Abbott Laboratories Stock Looks Ridiculously Overpriced

Why Abbott Laboratories Stock Looks Ridiculously Overpriced

Abbott Laboratories (NYSE: ABT) has had a volatile couple of years. It benefited from COVID-related tests boosting its sales, but last year it ran into manufacturing issues that affected its baby formula production and hurt sales in its nutritional segment. The business is now getting back to normal, but the problem is that its valuation still needs to come down significantly before it's a worthwhile buy.